InMed Pharmaceuticals - Developing cannabinol (CBN)
InMed has announced that the cannabinoid that is the basis for both its epidermolysis bullosa (EB) and glaucoma programs is cannabinol (CBN). This...
748 Views
InMed Pharmaceuticals - CTA filed on schedule
InMed Pharmaceuticals recently announced that it filed a Clinical Trial Application (CTA) in the Netherlands for INM-755, which is being developed...
728 Views
InMed Pharmaceuticals - Biosynthesis and INM-750 Progress on Track
InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa...
50 Views